We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use
Read MoreHide Full Article
Merck (MRK - Free Report) announced that the European Commission has approved its blockbuster drug Keytruda for treating certain patients with adjuvant renal cell carcinoma (RCC) in the European Union (EU).
The EC has approved Keytruda, a PD-1 inhibitor, as an adjuvant treatment for adult patients with RCC at intermediate-high or high risk of recurrence, following nephrectomy or following nephrectomy and resection of metastatic lesions.
Following the EC approval, Keytruda became the first immunotherapy approved as an adjuvant therapy in Europe for such patients with RCC.
The approval for Keytruda is based on data from the phase III KEYNOTE-564 study that evaluated Keytruda against placebo as an adjuvant therapy in 994 patients having intermediate-high or high risk of recurrence of RCC. Data from the study demonstrated that Keytruda achieved statistically significant improvement in disease-free survival (DFS), reducing the risk of disease recurrence or death by 32% compared to placebo.
Last November, Merck received approval for Keytruda in a similar indication in RCC in the United States.
Merck’s stock has risen 3.4% this year so far in comparison with the industry’s 13.8% rise.
Image Source: Zacks Investment Research
RCC is the most common form of kidney cancer. Per Merck, RCC accounts for the majority of kidney cancer diagnosis.
Keytruda is already approved in both the United States and EU as a first-line treatment of adult patients with advanced RCC, in combination with Pfizer’s (PFE - Free Report) axitinib.
Axitinib is marketed by Pfizer under the trade name Inlyta. Inlyta is also approved as monotherapy in both the United States and the EU for treating advanced RCC in adult patients who have failed a previous treatment regimen.
Pfizer’s Inlyta delivered a strong performance, driven by continued adoption in the United States and Europe. During the third quarter, Pfizer recorded $256 million in revenues from Inlyta sales.
Keytruda, which is the key revenue generator for Merck, is already approved for the treatment of many cancers globally. During third-quarter 2021, Merck recorded $4.5 billion in sales from Keytruda. Sales of the drug are gaining from its usage for the treatment of lung cancer and increasing use in other cancer indications. Keytruda is continuously growing and expanding into new indications and markets globally.
Merck is also evaluating Keytruda across a wide number of indications that are progressing well. In fact, Keytruda is being studied for more than 30 types of cancer indications in more than 1700 studies, including combination studies. Label expansions for new cancer indications, if approved, can further boost sales.
Bristol Myers (BMY - Free Report) markets its own immuno-oncology drug, Opdivo, which is approved for various oncology indications and poses stiff competition to Keytruda in many targeted indications. In fact, Bristol Myers’ Opdivo is approved as both monotherapy and in combination with marketed drugs Yervoy and Cabometyx for the treatment of adults with advanced RCC.
For the third quarter, Bristol Myers recorded $1.9 billion in revenues from sales of Opdivo.
Eli Lilly’s earnings per share estimates for 2022 have increased from $8.42 to $8.45 in the past 30 days. Shares of Eli Lilly have risen 12.7% in the past year.
Earnings of Eli Lilly missed estimates in three of the last four quarters while beating the mark in one, delivering a surprise of 0.5%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use
Merck (MRK - Free Report) announced that the European Commission has approved its blockbuster drug Keytruda for treating certain patients with adjuvant renal cell carcinoma (RCC) in the European Union (EU).
The EC has approved Keytruda, a PD-1 inhibitor, as an adjuvant treatment for adult patients with RCC at intermediate-high or high risk of recurrence, following nephrectomy or following nephrectomy and resection of metastatic lesions.
Following the EC approval, Keytruda became the first immunotherapy approved as an adjuvant therapy in Europe for such patients with RCC.
The approval for Keytruda is based on data from the phase III KEYNOTE-564 study that evaluated Keytruda against placebo as an adjuvant therapy in 994 patients having intermediate-high or high risk of recurrence of RCC. Data from the study demonstrated that Keytruda achieved statistically significant improvement in disease-free survival (DFS), reducing the risk of disease recurrence or death by 32% compared to placebo.
Last November, Merck received approval for Keytruda in a similar indication in RCC in the United States.
Merck’s stock has risen 3.4% this year so far in comparison with the industry’s 13.8% rise.
RCC is the most common form of kidney cancer. Per Merck, RCC accounts for the majority of kidney cancer diagnosis.
Keytruda is already approved in both the United States and EU as a first-line treatment of adult patients with advanced RCC, in combination with Pfizer’s (PFE - Free Report) axitinib.
Axitinib is marketed by Pfizer under the trade name Inlyta. Inlyta is also approved as monotherapy in both the United States and the EU for treating advanced RCC in adult patients who have failed a previous treatment regimen.
Pfizer’s Inlyta delivered a strong performance, driven by continued adoption in the United States and Europe. During the third quarter, Pfizer recorded $256 million in revenues from Inlyta sales.
Keytruda, which is the key revenue generator for Merck, is already approved for the treatment of many cancers globally. During third-quarter 2021, Merck recorded $4.5 billion in sales from Keytruda. Sales of the drug are gaining from its usage for the treatment of lung cancer and increasing use in other cancer indications. Keytruda is continuously growing and expanding into new indications and markets globally.
Merck is also evaluating Keytruda across a wide number of indications that are progressing well. In fact, Keytruda is being studied for more than 30 types of cancer indications in more than 1700 studies, including combination studies. Label expansions for new cancer indications, if approved, can further boost sales.
Bristol Myers (BMY - Free Report) markets its own immuno-oncology drug, Opdivo, which is approved for various oncology indications and poses stiff competition to Keytruda in many targeted indications. In fact, Bristol Myers’ Opdivo is approved as both monotherapy and in combination with marketed drugs Yervoy and Cabometyx for the treatment of adults with advanced RCC.
For the third quarter, Bristol Myers recorded $1.9 billion in revenues from sales of Opdivo.
Merck & Co., Inc. Price
Merck & Co., Inc. price | Merck & Co., Inc. Quote
Zacks Rank & Stock to Consider
Merck currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the same sector is Eli Lilly (LLY - Free Report) , which carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Eli Lilly’s earnings per share estimates for 2022 have increased from $8.42 to $8.45 in the past 30 days. Shares of Eli Lilly have risen 12.7% in the past year.
Earnings of Eli Lilly missed estimates in three of the last four quarters while beating the mark in one, delivering a surprise of 0.5%, on average.